Veracyte (VCYT) Stock Forecast & Price Target

Veracyte is supported by a durable growth engine in genomic diagnostics, with 3Q26 revenue of $151.8M up 15.1% and non-GAAP EPS of $0.51 beating consensus, while management still preserved adjusted EBITDA margin guidance of over 26% despite trimming revenue outlooks. The core thesis remains intact because Afirma continues to show high-single-digit growth, Decipher still delivers strong double-digit growth, and new or expanding assays like Prosigna, TrueMRD, and UroAmp can extend the company’s addressable market and diversify growth beyond prostate and thyroid testing. Financial strength also reinforces the outlook, as Veracyte generated $38.0M of free cash flow in 3Q26, ended with $371M of cash and no debt, and authorized a $100M share repurchase program.

Veracyte is facing a weakening fundamental setup as management’s 2027 guide points to only ~10% test volume growth and mid-single-digit revenue growth, far below prior expectations, while Decipher growth has already been cut to 12,000–15,000 tests and Afirma is only expected to grow ~5%. The gap between volume and revenue reflects lower prior-period collections, the roll-off of Afirma’s v2 transcriptome workflow, and mix dilution from lower-ASP Decipher Bladder and Prosigna, which lacks broad reimbursement and may price near cost. With slower growth, rising OpEx from a 30% larger urology sales push, and FY27 adjusted EBITDA margin only ~22% before reaching ~25% as it exits 2027, the stock appears vulnerable to a persistent peer valuation discount.